Nintedanib Ipf Al (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting fibroblast activation, angiogenesis and abnormal cell proliferation. This multi‑target inhibition reduces scar tissue formation in the lungs and limits the growth of certain cancer cells.

The prescribed dose of Nintedanib Ipf Al is determined by the treating physician based on the specific indication, patient characteristics and tolerability. Clinicians follow approved labeling and adjust the regimen as needed; patients should follow the exact dosing instructions provided by their healthcare professional.

Safety of Nintedanib during pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, and it is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, as determined by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow lung function decline, Nintedanib targets a broader range of tyrosine kinases, which may provide additional benefit in certain cancers and systemic sclerosis‑related disease. Choice of therapy depends on efficacy, tolerability, drug‑interaction profile and physician judgment.

Nintedanib Ipf Al should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the product in its original packaging until use and avoid exposure to high humidity or extreme temperatures to maintain stability.

Nintedanib Ipf Al is administered orally, usually with food to lessen gastrointestinal discomfort. Patients swallow the tablets whole with a full glass of water and should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include liver injury (elevated transaminases or hepatic failure), major bleeding events, cardiovascular complications such as myocardial infarction or stroke, gastrointestinal perforation, and severe infections. Patients should report any signs of abdominal pain, unusual bruising, yellowing of the skin or eyes, or sudden chest pain to their clinician promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment, those with active bleeding disorders, and individuals who are pregnant or breastfeeding unless the benefits outweigh the risks. Caution is also advised for patients with significant cardiovascular disease, uncontrolled hypertension, or a history of gastrointestinal ulceration.